The Effect of Molecular Diagnostics on the Treatment of Glioma

Purpose of Review This review summarizes the use of molecular diagnostics in glioma and its effect on the development of novel therapeutics and management decisions. Recent Findings Genomic and proteomic profiling of brain tumors has provided significant expansion of our understanding of oncogenesis...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology reports 2017-04, Vol.19 (4), p.26-26, Article 26
Main Authors: Bush, Nancy Ann Oberheim, Butowski, Nicholas
Format: Article
Language:English
Subjects:
Animals
Brain Neoplasms - diagnosis
Brain Neoplasms - drug therapy
Brain Neoplasms - genetics
Drug Discovery - methods
Glioma - diagnosis
Glioma - drug therapy
Glioma - genetics
Humans
Medicine
Medicine & Public Health
Neuro-oncology (S Nagpal
Oncology
Pathology, Molecular - methods
Proteomics - methods
Section Editor
Topical Collection on Neuro-oncology
Transcriptome - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review This review summarizes the use of molecular diagnostics in glioma and its effect on the development of novel therapeutics and management decisions. Recent Findings Genomic and proteomic profiling of brain tumors has provided significant expansion of our understanding of oncogenesis, characterization, and prognostication of brain tumors. Molecular markers such as MGMT, EGFR, IDH, 1p19q, ATRX, TERT, FGFR-TACC, and BRAF are now being used to classify brain tumors as well as influence management decisions. Several of these markers are also being used as therapeutic targets. Summary We review the use of several molecular diagnostics in gliomas and discuss their impact on drug development and clinical trial design. In the future, molecular characterization based on a specific genomic, proteomic as well as transcriptomes for bioformatics analysis will provide clinicians the ability to rationally select drugs with actionable targets for each patient.
ISSN:1523-3790
1534-6269
DOI:10.1007/s11912-017-0585-6